Navigation Links
The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
Date:8/6/2008

DOYLESTOWN, Pa., Aug. 6 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY) today announced that Gerard M. Gleeson has been named to succeed George J. Longo, who will be retiring from the Company on September 5, 2008, as Vice President, Chief Financial Officer and as a member of the Board of Directors. Mr. Gleeson joined The Quigley Corporation in 1998 and has served in management positions including Corporate Controller of the Company since 2004.

Mr. Gleeson is a Fellow of the Association of Chartered Certified Accountants, the global body of professional accountants, with extensive business and industry acumen that includes tenure as Chief Financial Officer in Ireland for a subsidiary of Allergan Inc., a multi-national pharmaceutical company. Additionally, Mr. Gleeson has senior financial management experience in the retail and service industries.

Guy J. Quigley, Chairman, President and Chief Executive Officer said, "George Longo has served as CFO and a Director of the Company since 1997 and played a vital role in The Quigley Corporation's successes throughout the years. We are sorry to see him leave and appreciate all of his contributions to the Company and wish him well in his retirement."

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities and Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

CONTACT:

George J. Longo Carl Hymans

Vice President, CFO G.S. Schwartz & Co.

(215) 345-0919 (212) 725-4500

carlh@schwartz.com


'/>"/>
SOURCE The Quigley Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
2. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
3. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
4. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
5. Brooke Franchise Corporation Announces Selected July Results
6. MedThink Communications Retained by NanoBio Corporation
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
9. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
10. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
11. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been paid ... who become dependent on opioid painkillers has fallen short. From 1999 until 2010, fatal ... 237% increase in fatal overdoses in male populations.(1) , The proportion of women using ...
(Date:2/27/2017)... ... ... Elisa Guajardo Carothers is not your typical author. She went from working as a movie ... writes about God, when she isn’t swimming as a performing mermaid. , Her book isn’t ... Satan),” she offers a comedic look at the dysfunctions of God’s family, before Lucifer was ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , ... as a tool to characterize particle size distributions in the field of geoscience ... and novel scientific findings. It describes methods of optimized and standardized sample collection, ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... POUGHKEEPSIE, N. ... ) has disclosed that despite scientific studies, the Center for Disease Control ( CDC ... Lyme disease . Kenneth B. Liegner, M.D. has compiled into a single volume ...
(Date:2/27/2017)... ... 2017 , ... Sunshine Coast Health Centre (SCHC), one of ... https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered massage ... commitment to innovation in drug rehab and alcohol treatment strategies beyond a "punishment" ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Following receiving CE Marking in ... s AMAR is a major milestone for the country where the ... ound care market in Israel ... for inclusion in the National Health Basket , Israel ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment ...
(Date:2/24/2017)... and Markets has announced the addition of the "Dry eye Drugs ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... following questions: What are the key drugs ... in the Global Dry eye market? What are the ...
(Date:2/24/2017)... , Feb. 23, 2017 The ... of the PhenoTest BC Kit, performed on the ... identify organisms that cause bloodstream infections and provide ... to respond to (antibiotic sensitivity). The test also ... provide this important information, which can guide antibiotic ...
Breaking Medicine Technology: